Clinical trial
Immunogenicity and Safety of a SARS-CoV-2 Vaccine LYB001 in Healthy Adults: a Randomized, Double Blinded, Placebo-controlled Phase Ⅱ Trial and a Single-arm, Open-label Phase Ⅲ Trial for Extended Safety
NCT05137444 is registered in ClinicalTrials.gov with Yantai Patronus Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety of a SARS-CoV-2 Vaccine LYB001 in Healthy Adults: a Randomized, Double Blinded, Placebo-controlled Phase Ⅱ Trial and a Single-arm, Open-label Phase Ⅲ Trial for Extended Safety
- Lead sponsor
- Yantai Patronus Biotech Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- January 31, 2022
- Completion date
- May 31, 2023
- Enrollment
- 1,900 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.